The DUSK Trial
Phase III randomized trial of thrombectomy versus standard medical therapy for distal medium vessel occlusion stroke. Active and enrolling: 584 patients, up to 50 sites. NCT05983757.
About DUSKOur research team publishes findings in leading peer-reviewed journals, contributing to neurovascular research advancement.
Phase III randomized trial of thrombectomy versus standard medical therapy for distal medium vessel occlusion stroke. Active and enrolling: 584 patients, up to 50 sites. NCT05983757.
About DUSKOur Clinical Trials Unit is preparing further multicenter trials, pending funding.
Clinical Trials UnitThe patient-level pooled analysis of the four vertebrobasilar thrombectomy trials: BEST, BASICS, ATTENTION and BAOCHE.
With our Statistical and Data Science Core Lab: ATLAS ER, the RESILIENT trials and HEMERA-1.
About the coreAn interview with Dr. Doheim on why stroke is poorly suited to one-size-fits-all care, the recanalization paradox, and individualized treatment estimation.
Read UPMC Physician ResourcesSeptember 4, 2026A validated model that estimates each patient's chance of functional independence with thrombectomy and with medical management (Annals of Neurology, 2026).
Read Inside UPMCApril 2, 2026In more than 4,500 patients across four hubs and 60 community hospitals, scan sharing shortened transfers and widened access to thrombectomy (Journal of Neurology, Neurosurgery and Psychiatry).
Read








